Neogen Chemicals Raises ₹600 Crore Via QIP

Neogen Chemicals Limited

has raised Rs 600 crore through a Qualified Institutions Placement, allotting 26,60,753 shares at Rs 2,255 each. The issue was oversubscribed 6.5 times. The allotment price of Rs 2,255 was above the regulatory floor price of Rs 2,189.73, so shares went out at a premium rather than a discount. Paid up equity capital rises from Rs 27.38 crore to Rs 30.04 crore after the issue. Net debt is expected to fall below Rs 150 crore, and proceeds are earmarked for the Dahej Phase 1 facility and the Pakhajan Phase 2 greenfield battery materials project, where trial production runs are already underway. In Q1 FY27, revenue grew 34% year on year to Rs 250 crore, EBITDA rose 53% to Rs 48 crore, and PAT rose 67% to Rs 17 crore. The detail that stands out to me is the pricing, not just the oversubscription. Allotting at a premium to the floor price, rather than the discount common in QIPs, suggests institutional buyers were competing for allocation, not negotiating it down. That is a stronger signal than the 6.5 times subscription figure alone. The near-term profit growth is coming from the existing specialty chemicals business, not battery materials yet, since both new facilities are still at trial stage. I would treat this quarter's numbers as the base business performing well, with the battery scale-up still to be proven through H2 FY27. I am watching trial-to-commercial timelines at Dahej and Pakhajan, confirmation that net debt falls below Rs 150 crore, and any new supply contracts with electrolyte buyers. This raise removes a funding overhang and de-risks the battery materials build-out. I am watching over a 3 to 12 month horizon into commercial scale-up in H2 FY27. Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations.